Madison, WI, United States of America

Asako Tetsubayashi

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Illumina Corporation. Active years: 2022-2024.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Asako Tetsubayashi: Innovator in RNA Depletion Technologies

Introduction

Asako Tetsubayashi is a prominent inventor based in Madison, WI (US). She has made significant contributions to the field of molecular biology, particularly in the area of RNA depletion technologies. With a total of 2 patents, her work has been instrumental in advancing research methodologies.

Latest Patents

Tetsubayashi's latest patents focus on nuclease-based RNA depletion. The present disclosure is related to methods and materials for depleting unwanted RNA species from a nucleic acid sample. In particular, it describes how to remove unwanted rRNA, tRNA, mRNA, or other RNA species that could interfere with the analysis, manipulation, and study of target RNA molecules in a sample. This innovative approach enhances the accuracy and efficiency of RNA analysis.

Career Highlights

Asako Tetsubayashi is currently employed at Illumina Corporation, a leading company in the field of genomics. Her work at Illumina has allowed her to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Some of her notable coworkers include Scott Kuersten and Frederick W Hyde. Their collaborative efforts have further enriched the research environment at Illumina Corporation.

Conclusion

Asako Tetsubayashi's contributions to RNA depletion technologies exemplify her innovative spirit and dedication to advancing scientific research. Her patents and work at Illumina Corporation continue to influence the field of molecular biology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…